169 related articles for article (PubMed ID: 16281942)
1. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice.
Yamashita N; Osato M; Huang L; Yanagida M; Kogan SC; Iwasaki M; Nakamura T; Shigesada K; Asou N; Ito Y
Br J Haematol; 2005 Nov; 131(4):495-507. PubMed ID: 16281942
[TBL] [Abstract][Full Text] [Related]
2. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y
Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
4. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
5. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.
Song WJ; Sullivan MG; Legare RD; Hutchings S; Tan X; Kufrin D; Ratajczak J; Resende IC; Haworth C; Hock R; Loh M; Felix C; Roy DC; Busque L; Kurnit D; Willman C; Gewirtz AM; Speck NA; Bushweller JH; Li FP; Gardiner K; Poncz M; Maris JM; Gilliland DG
Nat Genet; 1999 Oct; 23(2):166-75. PubMed ID: 10508512
[TBL] [Abstract][Full Text] [Related]
6. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
Cammenga J; Niebuhr B; Horn S; Bergholz U; Putz G; Buchholz F; Löhler J; Stocking C
Cancer Res; 2007 Jan; 67(2):537-45. PubMed ID: 17234761
[TBL] [Abstract][Full Text] [Related]
7. Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions.
Béri-Dexheimer M; Latger-Cannard V; Philippe C; Bonnet C; Chambon P; Roth V; Grégoire MJ; Bordigoni P; Lecompte T; Leheup B; Jonveaux P
Eur J Hum Genet; 2008 Aug; 16(8):1014-8. PubMed ID: 18478040
[TBL] [Abstract][Full Text] [Related]
8. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
Osato M
Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
[TBL] [Abstract][Full Text] [Related]
9. The Runx genes: lineage-specific oncogenes and tumor suppressors.
Cameron ER; Neil JC
Oncogene; 2004 May; 23(24):4308-14. PubMed ID: 15156187
[TBL] [Abstract][Full Text] [Related]
10. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies.
Minelli A; Maserati E; Rossi G; Bernardo ME; De Stefano P; Cecchini MP; Valli R; Albano V; Pierani P; Leszl A; Sainati L; Lo Curto F; Danesino C; Locatelli F; Pasquali F
Genes Chromosomes Cancer; 2004 Jul; 40(3):165-71. PubMed ID: 15138996
[TBL] [Abstract][Full Text] [Related]
11. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.
Nick HJ; Kim HG; Chang CW; Harris KW; Reddy V; Klug CA
Blood; 2012 Feb; 119(6):1522-31. PubMed ID: 21937700
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
13. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Miething C; Grundler R; Mugler C; Brero S; Hoepfl J; Geigl J; Speicher MR; Ottmann O; Peschel C; Duyster J
Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4594-9. PubMed ID: 17360569
[TBL] [Abstract][Full Text] [Related]
14. LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation.
Dai HP; Xue YQ; Zhou JW; Li AP; Wu YF; Pan JL; Wang Y; Zhang J
Genes Chromosomes Cancer; 2009 Dec; 48(12):1027-36. PubMed ID: 19760607
[TBL] [Abstract][Full Text] [Related]
15. RUNX1 haploinsufficiency results in granulocyte colony-stimulating factor hypersensitivity.
Chin DW; Sakurai M; Nah GS; Du L; Jacob B; Yokomizo T; Matsumura T; Suda T; Huang G; Fu XY; Ito Y; Nakajima H; Osato M
Blood Cancer J; 2016 Jan; 6(1):e379. PubMed ID: 26745853
[TBL] [Abstract][Full Text] [Related]
16. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
Steensma DP; Gibbons RJ; Mesa RA; Tefferi A; Higgs DR
Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106
[TBL] [Abstract][Full Text] [Related]
17. A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies.
Kirito K; Sakoe K; Shinoda D; Takiyama Y; Kaushansky K; Komatsu N
Haematologica; 2008 Jan; 93(1):155-6. PubMed ID: 18166807
[TBL] [Abstract][Full Text] [Related]
18. Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma.
Wotton S; Stewart M; Blyth K; Vaillant F; Kilbey A; Neil JC; Cameron ER
Cancer Res; 2002 Dec; 62(24):7181-5. PubMed ID: 12499254
[TBL] [Abstract][Full Text] [Related]
19. A distinct epigenetic signature at targets of a leukemia protein.
Rossetti S; Hoogeveen AT; Liang P; Stanciu C; van der Spek P; Sacchi N
BMC Genomics; 2007 Feb; 8():38. PubMed ID: 17266773
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel Runx1 (AML1) translocation partner genes SH3D19, YTHDf2, and ZNF687 in acute myeloid leukemia.
Nguyen TT; Ma LN; Slovak ML; Bangs CD; Cherry AM; Arber DA
Genes Chromosomes Cancer; 2006 Oct; 45(10):918-32. PubMed ID: 16858696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
